Johnson & Johnson operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Johnson & Johnson with three other major healthcare and pharmaceutical companies: Bristol-Myers Squibb Company (2020 sales of $42.52 billion of which 28% was Prioritized Brands-Revlimid), Baxter International Inc. ($11.67 billion of which 52% was Americas), and Novartis AG which is based in SWITZERLAND (46.58 billion Swiss Francs [US$50.41 billion] of which 78% was Innovative Medicines).

Sales Analysis. During the second quarter of 2021, sales at Johnson & Johnson totalled $23.31 billion. This is an increase of 27.1% from the $18.34 billion in sales at the company during the second quarter of 2020. This was the biggest same quarter rise in sales at Johnson & Johnson in the previous 35 quarters. During the first two quarters of 2021, sales totalled $45.63 billion, which is 16.9% higher than through the first two quarters of 2020. During the year ended December of 2020, sales at Johnson & Johnson were $82.58 billion. This is a very small increase of 0.6% versus 2019, when the company's sales were $82.06 billion. This was the fifth consecutive year of sales increases at Johnson & Johnson (and since 2015, sales have increased a total of 18%). Sales of Pharmaceutical saw an increase that was more than double the company's growth rate: sales were up 8.0% in 2020, from $42.20 billion to $45.57 billion. Johnson & Johnson also saw significant increases in sales in Consumer (up 1.1% to $14.05 billion) . Not all segments of Johnson & Johnson experienced an increase in sales in 2020: sales of Medical Devices fell 11.6% to $22.96 billion.